Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Takeda’s Uloric (febuxostat) ended a forty-year drought for new gout treatments when FDA approved the oral drug for chronic disease on Feb. 13, but a pipeline stocked with new drugs holds the promise of a shorter wait for the next gout therapy.

You may also be interested in...

AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk

Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.

Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End

Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.

As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid

PHILADEPHIA – Though Takeda's gout therapy Uloric (febuxostat) has broken a 40-year dry spell in the market, physicians and researchers are hoping more drugs will be approved that can reduce serum uric acid well below the standard 6 mg/dL benchmark. Safety, though, could be a hang-up.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts